Automate Your Wheel Strategy on DRRX
With Tiblio's Option Bot, you can configure your own wheel strategy including DRRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DRRX
- Rev/Share 0.0169
- Book/Share 0.1867
- PB 10.0187
- Debt/Equity 0.3423
- CurrentRatio 1.2266
- ROIC -2.2289
- MktCap 58049662.0
- FreeCF/Share -0.5113
- PFCF -3.6576
- PE -11.8153
- Debt/Assets 0.1381
- DivYield 0
- ROE -0.9279
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout
Published: July 29, 2025 by: Benzinga
Sentiment: Positive
Bausch Health Companies Inc. BHC on Tuesday agreed to indirectly acquire DURECT Corp DRRX, including a novel therapeutic molecule, larsucosterol.
Read More
DRRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of DURECT Corporation Is Fair to Shareholders
Published: July 29, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of DURECT Corporation (NASDAQ: DRRX) to Bausch Health Companies Inc. for $1.75 per share is fair to DURECT shareholders. Halper Sadeh encourages DURECT shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether DURECT and it.
Read More
DURECT Corporation (DRRX) Q4 2024 Earnings Call Transcript
Published: March 26, 2025 by: Seeking Alpha
Sentiment: Neutral
DURECT Corporation (NASDAQ:DRRX ) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Co-Founder, Chief Executive Officer, President, Director Norman Sussman - Chief Medical Officer WeiQi Lin - Executive Vice President, Research & Development and Principal Scientist Conference Call Participants François Brisebois - Oppenheimer & Company Karl Burns - Northland Capital Markets Thomas Yip - H.C. Wainwright Operator Greetings and welcome to the DURECT Corporation Fourth Quarter and Full-Year 2024 Earnings Conference Call.
Read More
Durect (DRRX) Reports Q4 Loss, Lags Revenue Estimates
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Negative
Durect (DRRX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.27 per share a year ago.
Read More
About DURECT Corporation (DRRX)
- IPO Date 2000-09-28
- Website https://www.durect.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO James E. Brown D.V.M.
- Employees 21